The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.

Pieter MartensHanne BeliënMatthias DupontPieter VandervoortWilfried Mullens

Published in: Cardiovascular therapeutics (2018)

Switching therapy in eligible HFrEF patients from a RAS-blocker to sacubitril/valsartan induces beneficial reverse remodeling of both metrics of systolic as diastolic function.

Keyphrases

ejection fraction
heart failure
left ventricular
blood pressure
end stage renal disease
newly diagnosed
prognostic factors
stem cells
atrial fibrillation
bone marrow
wild type